Inhibrx Biosciences Stock Soars 60% Post Positive Chondrosarcoma Trial Results

Shares of Inhibrx Biosciences (NASDAQ:INBX) witnessed a dramatic surge in premarket trading, exceeding 60%, after the announcement of positive topline results from its registrational trial of ozekibart (INBRX-109) for chondrosarcoma. The company’s stock jumped from $31.52 to $46.30 on October 24, 2025, at 7:44 AM EDT, marking a significant increase of over 63%. This positive development comes as the ChonDRAgon study met its primary endpoint, demonstrating statistically significant improvement in median progression-free survival compared to placebo.